Why the Transdermal Delivery of Selegiline (6 Mg/24 Hr) Obviates the Need for a Dietary Restriction on Tyramine

SHELDON H. PRESKORN, MD, is Professor and Chairman, Department of Psychiatry, University of Kansas School of Medicine-Wichita, and Chief Executive Officer and Medical Director, Clinical Research Institute, Wichita, Kansas. He has more than 28 years of drug development research experience at all levels (i.e., preclinical through Phase IV) and has been a principal investigator on over 225 clinical trials including every antidepressant marketed in the United States over the last 20 years. Dr. Preskorn maintains a website at 〈www.preskorn.com〉 where readers can access previous columns and other publications. Disclosure: Relative to the transdermal delivery system for selegiline, Dr. Preskorn was a principal investigator for registration trials of the product for the treatment of major depression, a consultant to Somerset and Bristol-Myers Squibb during the approval process, and a presenter at the FDA Psychopharmacology Advisory Committee meeting on the product.